Published Study Shows Novel Compounds May Help Protect Against Respiratory Depression : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

Published Study Shows Novel Compounds May Help Protect Against Respiratory Depression

June 22, 2009

Irvine, CA – (RPRN) 6/22/2009 -- A paper that appears in the June 2009 issue of Anesthesiology details how AMPAKINE CX717, a Phase II compound created by Irvine, California-based neuroscience company Cortex Pharmaceuticals, demonstrated the rescue of fentanyl-induced respiratory depression and sleep apnea in rats. In this same study, CX717 demonstrated equal efficacy with the opioid -antagonist Naloxone, a drug used to counter the effects of opioids on suppression of breathing. CX717 did not, however, interfere with the action of pain-killing opiates. This offers a distinct advantage compared with Naloxone and could provide a novel therapeutic means of treating those patients who are particularly prone to breathing depression with opiates while achieving maximum pain relief.

“The paper focuses on how CX717 enhances the safety of opiate analgesic use during surgery,” explains University of Alberta professor Dr. John J. Greer, who led the animal study. “Patients are usually given an opiate to mediate pain during surgery. Typically, opiates cause respiratory depression in about ten to fifteen percent of patients, which is usually countered by decreasing the amount of opiate. The problem then becomes patients awakening from surgery into pain. The study’s hypothesis was that the AMPAKINE molecule can stimulate breathing without interfering with the ameliorative effects of analgesics.”

AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA-type glutamate receptor. Dr. Greer’s research team demonstrated that certain AMPAKINE compounds stimulate primitive areas of the brain called the pre-Botzinger Complex that controls breathing, without causing side effects. In animal models, the compounds were shown to enhance the respiratory drive and breathing rhythm in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

“We tested this hypothesis with adult Sprague-Dawley rats, which were given the potent opioid fentanyl,” Dr. Greer explains. “When these rats were administered AMPAKINE CX717 after taking the opiate, their breathing came back very strong. During the study, CX717 was shown not only to protect breathing rates; it also demonstrated the potential to prevent upper airways from collapsing. We then co-administered the AMPAKINE with the opiate as a cocktail, and found that the rats did not experience respiratory depression.”

These results suggest that high-risk post-operative surgical patients, including people sixty-five years and older, those suffering from a history of sleep apnea, patients struggling with obesity, those with a history of respiratory disease such as Chronic Obstructive Pulmonary Disease (COPD), and patients on a regimen of heavy background opiates for the treatment of chronic pain, might be given AMPAKINE preemptively in order to reduce the risk of respiratory depression during surgery.

“CX717 appears to allow clinicians to reduce the incidents of respiratory depression during surgery in some cases, and, in other cases, be used as a rescue for people overdosing on opiates,” says Dr. Greer. “CX717 also generalized across families of drugs not limited to opioids. Combinations of alcohol and barbiturates can cause severe instances of respiratory depression, and CX717 was shown to work in these cases as well. This may lead the way in turning these compounds into rescue therapies.”

These animal studies were later replicated in two Phase II respiratory depression clinical studies involving forty human volunteers in Germany. The next step will be the development of CX717 in intravenous form, with repeated Phase II tests in human trials via intravenous dosing.

“These advances will help patients whose pain cannot be treated effectively with opioids due to the unwanted side effect of a depression of breathing,” says Dr. Greer. “Administration of AMPAKINE compounds can overcome this problem and lead to a significant improvement in pain management, as well as guard against deaths caused by opioid overdose.”

For more information, log on to www.cortexpharm.com.

Media Contact:

Janet Vasquez

The Investor Relations Group

212-825-3210

jvasquez@investorrelationsgroup.com

About the author:

Janet Vasquez, Director of Corporate Communications

About IRG

We are The Investor Relations Group (IRG), a full-service corporate communications firm that provides investor relations and public relations services to nano-, micro- and small-cap companies providing them with the equivalent in-house services of a large-cap company.

http://www.investorrelationsgroup.com

Click here to see all news from this author/company

Filed Under: Health and Fitness, Lifestyle, PRESS RELEASE, YAHOO NEWS, FDA- Pharmaceutical news, SCIENCE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Coffee With Dr. Stewart

Austin, TX 11/25/14 · A brother and sister bring an exciting new...

Arki Kickstarter reaches $100K target in 13 days

Los Angeles/Seoul, Korea 11/24/14 · One step closer to a walking revolution The kickstarter...

Zikto taking award-winning Arki to Startup Nations Summit

Seoul, Korea 11/22/14 · Zikto taking award-winning Arki to Startup Nations Summit The...

The End of Transparency? Don't be a fraud target

Carrollton, TX 11/18/14 · - Over the years, progressive and productive societies...

Ultraseal international in finals of Midlands Business Awards 2015

Coventry, UK 11/14/14 · Ultraseal International, which exports to the automotive supply...

Arki: Hot New Wearable Tech Setting a Cracking Pace on Kickstarter

San Francisco, CA 11/14/14 · Update for November 21: 412 Backers $90,034 pledged...

UpWest Labs Unveils Details of Its Eighth Batch of Startups, Ranging From Genetics to 3D Design

Palo Alto, California 11/11/14 · Accelerator continues to support innovative entrepreneurs with its...

Modern Casting Impregnation helps automakers to avoid warranty claims on engines

Novi, MI 11/11/14 · Automakers can save money and avoid costly warranty...

The Evolution of Walking: Wearable Tech steps up to a new level

San Francisco, CA 11/11/14 · Arki: Finally Wearable Meets Fashion – Wearable technology is one of 2014’s...

GeneSegues Awarded $1 Million Phase II NIH/NCI Research Contract for Nanoencapsulated RNAi Cancer Therapeutic

MINNEAPOLIS, MN 11/10/14 · Highly Competitive NIH Program Validates Potential of GS-10...

More Than 400 .Onion Addresses Targeted as Part of Global Enforcement Action on Tor Network

WASHINGTON 11/07/14 · More Than 400 .Onion Addresses, Including Dozens of...

Learn about Wine in Your Pjs - A New Kind of Wine Class

SAUSALITO, CA. 11/04/14 · The Wine Key announced today it's first virtual...

XCEL Professional Services Has Made a Huge Change to Move Our Company Forward

Calgary, AB 11/04/14 · Introducing Rob Hay: The New President of XCEL...